What one share of Metavia holds
We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We have two programs focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and obesity.
Metavia’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.74 |
|---|---|
| Cash and investments | $1.92 |
| Book value | $1.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$477.57 | — | — | — | — |
| 2023 | — | −$27.05 | $0.11 | −$23.53 | — | $37.41 |
| 2024 | — | −$39.13 | $0.01 | −$35.05 | — | $10.10 |
| 2025 | — | −$7.35 | $0.00 | −$8.89 | — | $2.31 |
Common questions about Metavia
How much does one share of Metavia earn?
Over the last 12 months, Metavia lost $3.74 for each share.
Does Metavia pay a dividend?
Metavia didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Metavia’s book value per share?
Metavia’s book value is $1.04 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Metavia have?
Each share of Metavia has $1.92 of cash and investments, as of June 30, 2026.
Has Metavia bought back shares?
Metavia’s share count rose about 5939% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.